SCHEMBL25225986

SCHEMBL25225986

CNc1ncc2nc(Br)c(NCCO)nc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 2/20 0.39
▸ KDM4E B2RXH2 4/20 0.36
▸ POLB P06746 2/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ MAPT P10636 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CCNA2 P20248 4/20 0.33
▸ CDK2 P24941 4/20 0.33
▸ CCNA1 P78396 4/20 0.33
▸ EGFR P00533 3/20 0.33
▸ TYRO3 Q06418 1/20 0.33
▸ MERTK Q12866 1/20 0.33
▸ GAS6 Q14393 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ PIK3C3 Q8NEB9 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GAA P10253 2/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30595895 1.00 FLT3 (0.39) FLT3KDM4EPOLBMAPK1MAPT
SCHEMBL27103103 0.78 FLT3 (0.39) FLT3KDM4EPOLBMAPK1MAPT
SCHEMBL29536830 0.76 FLT3 (0.40) FLT3KDM4EPOLBMAPK1MAPT
SCHEMBL25230025 0.76 FLT3 (0.40) FLT3KDM4EPOLBMAPK1MAPT
SCHEMBL25221516 0.76 KDM4E (0.51) FLT3KDM4EPOLBMAPK1LMNA
SCHEMBL29313773 0.68 CCNA2 (0.46) FLT3KDM4ECCNA2CDK2CCNA1
SCHEMBL25223077 0.67 CCNA2 (0.40) KDM4EPOLBMAPK1MAPTLMNA
SCHEMBL29537006 0.67 CCNA2 (0.40) KDM4EPOLBMAPK1MAPTLMNA
SCHEMBL2323296 0.66 KDM4E (0.43) KDM4EPOLBMAPK1MAPTLMNA
SCHEMBL27103106 0.66 PRKCH (0.35) EGFRIKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 — — CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 — — EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 FLT3 19/4885KDM4E 1096/4885POLB 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback